{"id":"NCT00373425","sponsor":"OSI Pharmaceuticals","briefTitle":"A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors","officialTitle":"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent TarcevaÂ® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2013-04","completion":"2014-06","firstPosted":"2006-09-08","resultsPosted":"2014-06-03","lastUpdate":"2015-09-17"},"enrollment":1252,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Non-small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Erlotinib","otherNames":["OSI-774","Tarceva"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Erlotinib","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a study to evaluate the effectiveness of erlotinib compared with a placebo sugar pill following complete surgical removal of the tumor with or without chemotherapy after surgery in Stage IB-IIIA NSCLC patients.","primaryOutcome":{"measure":"Disease Free Survival (DFS)","timeFrame":"Every 3 months during active phase and every 6 months during long term follow-up up to 5 years and yearly thereafter until the data cut-off date of 08 April 2013 (maximum time on follow-up was 64 months).","effectByArm":[{"arm":"Erlotinib","deltaMin":50.5,"sd":null},{"arm":"Placebo","deltaMin":48.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.3235"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":295,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","Czechia","France","Germany","Greece","Hungary","Italy","Poland","Romania","Russia","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["26324372"],"seeAlso":["https://www.astellasclinicalstudyresults.com/study.aspx?ID=OSI-774-302"]},"adverseEventsSummary":{"seriousAny":{"events":118,"n":611},"commonTop":["Rash","Diarrhoea","Pruritus","Cough","Dry skin"]}}